➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
AstraZeneca
Merck
McKinsey
Express Scripts

Last Updated: February 28, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ADVIL MIGRAINE LIQUI-GELS

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Advil Migraine Liqui-gels

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT01687101 STOPAIN in the Treatment of a Single Migraine Attack Completed Thomas Jefferson University N/A 2012-05-01 This is an open label pilot study of 25 subjects with a diagnosis of episodic migraine with or without aura. STOPAIN is an over-the-counter product that is used for the temporary relief of minor aches and pains of muscles and joints associated with simple backache, arthritis, strains, bruises and sprains. We plan to have subjects apply the product during a single migraine attack to see if it will alleviate the headache pain and associated symptoms.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Advil Migraine Liqui-gels

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004654 Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia Completed Yale University Phase 3 1996-01-01 OBJECTIVES: I. Evaluate migraine prophylaxis with soy protein isolate in patients with hereditary hemorrhagic telangiectasia. II. Assess whether soy protein isolate reduces the frequency and severity of epistaxis and gastrointestinal bleeding in these patients.
NCT00004654 Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia Completed National Center for Research Resources (NCRR) Phase 3 1996-01-01 OBJECTIVES: I. Evaluate migraine prophylaxis with soy protein isolate in patients with hereditary hemorrhagic telangiectasia. II. Assess whether soy protein isolate reduces the frequency and severity of epistaxis and gastrointestinal bleeding in these patients.
NCT00055484 A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects With Migraine Headache Completed Elan Pharmaceuticals Phase 2 2002-03-01 The purpose of this study is to determine if zonisamide is effective as a preventative medication for individuals with migraine headache.
NCT00069355 Propranolol for the Treatment of Acute Stress Disorder Completed National Institute of Mental Health (NIMH) Phase 2 2003-09-01 This 10-week study will examine whether propranolol, a medication that blocks the activity of the stress hormones adrenaline and noradrenaline, can relieve acute stress disorder (ASD) and symptoms from persisting long-term. ASD is a condition that some people develop soon after exposure to trauma. They may be anxious, depressed, have trouble sleeping, startle easily, have difficulties concentrating, and feel as though the event is happening again. Propranolol has been used for many years to treat high blood pressure and heart disease, and has been found useful in treating anxiety states such as social phobia and migraine. Men and women between 18 and 65 years of age who were recently exposed to trauma (between 1 and 3 weeks of evaluation in this study) may be eligible for this study. Candidates must be diagnosed with ASD and must have been mentally healthy before the traumatic event. They will be screened for the study with a medical and psychiatric interview, physical examination, electrocardiogram (EKG), and blood and urine tests. Participants will be evaluated with the following procedures: - Neuropsychological tests using pen-and-paper and computer tests to evaluate cognitive function, particularly memory, learning, attention and concentration, and vocabulary and naming. - Emotion-related performance tasks to determine if the study medication can weaken emotionally arousing information by blocking the activity of adrenaline and noradrenaline. Subjects perform emotion-related and neutral tasks, such as looking at pictures with neutral, pleasant, or unpleasant content, both before and after treatment with the study medication (see below). - Traumatic script exposure: Subjects recount the traumatic event that caused them to develop ASD. The description is summarized, recorded, and played back to the subject. During the playback, physiological responses, such as heart rate and skin conductance (sweating), are recorded using electrodes taped to the hand and chest. - Fear conditioning to evaluate the response to an unpleasant stimulus: Several mild electrical shocks are delivered to the wrists while the subject looks at colored squares. Heart rate and skin conductance are measured. - Magnetic resonance imaging (MRI) to examine brain structure. The subject lies on a table that is moved into the MRI scanner (a narrow cylinder containing a strong magnetic field) and must remain still during the actual scanning. Earplugs are worn to muffle loud noises caused by electrical switching of radio frequency circuits used in the scanning process. After the evaluation, participants are randomly assigned to receive either propranolol or placebo (a look-alike pill with no active ingredient) for 8 weeks During this time they are seen by a doctor once a week for 4 weeks and then once every other week for the rest of the study. At the end of the 8-week treatment period, participants undergo the same evaluation they had before beginning treatment (see above). The decision to continue treatment will then be decided based on the individual's clinical condition and whether he or she received propranolol or placebo.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Advil Migraine Liqui-gels

Condition Name

Condition Name for Advil Migraine Liqui-gels
Intervention Trials
Migraine 265
Migraine Disorders 76
Migraine Headache 46
Headache 37
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Advil Migraine Liqui-gels
Intervention Trials
Migraine Disorders 543
Headache 193
Migraine with Aura 41
Migraine without Aura 40
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Advil Migraine Liqui-gels

Trials by Country

Trials by Country for Advil Migraine Liqui-gels
Location Trials
Japan 96
Spain 69
Denmark 64
United Kingdom 62
Canada 61
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Advil Migraine Liqui-gels
Location Trials
California 126
New York 119
Florida 112
Missouri 107
Texas 96
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Advil Migraine Liqui-gels

Clinical Trial Phase

Clinical Trial Phase for Advil Migraine Liqui-gels
Clinical Trial Phase Trials
Phase 4 152
Phase 3 196
Phase 2/Phase 3 22
[disabled in preview] 129
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Advil Migraine Liqui-gels
Clinical Trial Phase Trials
Completed 325
Not yet recruiting 135
Recruiting 121
[disabled in preview] 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Advil Migraine Liqui-gels

Sponsor Name

Sponsor Name for Advil Migraine Liqui-gels
Sponsor Trials
GlaxoSmithKline 38
Merck Sharp & Dohme Corp. 37
Danish Headache Center 37
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Advil Migraine Liqui-gels
Sponsor Trials
Other 470
Industry 413
U.S. Fed 17
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
McKesson
Medtronic
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.